Immunotherapy for recurrent/metastatic head and neck cancer

Salvatore Alfieri, Stefano Cavalieri, Lisa Licitra

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: In the last decade, after cetuximab (anti-epidermal growth factor receptor), none of the novel investigated compounds has demonstrated benefit in head and neck squamous cell cancers (HNSCC), both in advanced and curative settings. Therefore, prognosis of recurrent/metastatic (R/M) HNSCC patients remains dismal, especially in platinum-refractory cohort. In the last few years, a new important class of drugs has affirmed its role. HNSCC, even if less 'immunogenic' than other malignancies (e.g. melanoma), was field of application of several new immune agents. To date, the most important data regard drugs acting on PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) axis that is a crucial checkpoint used by tumor for immune escape. Our purpose is to summarize the results of these PD-1/PD-L1 inhibitors, outlining some critical points and few practical suggestions.

RECENT FINDINGS: Nivolumab was recently approved by main regulatory agencies as second-line treatment for platinum-refractory R/M HNSCC. In the same setting, pembrolizumab was approved by FDA. Atezolizumab and durvalumab have already showed similar benefit in phase Ia and II studies, respectively.

SUMMARY: Anti-PD1/PD-L1 agents are new effective therapies in R/M HNSCC. Their combination with conventional/novel compounds, as well as a better selection of responding patients, could lead to improve current results.

Original languageEnglish
Pages (from-to)152-156
Number of pages5
JournalCurrent Opinion in Otolaryngology and Head and Neck Surgery
Volume26
Issue number2
DOIs
Publication statusPublished - Apr 2018

Fingerprint

Squamous Cell Neoplasms
Head and Neck Neoplasms
Immunotherapy
Head
Platinum
Tumor Escape
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Patient Selection
Melanoma
Ligands
Therapeutics
Neoplasms

Keywords

  • Antibodies, Monoclonal/therapeutic use
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Carcinoma, Squamous Cell/mortality
  • Disease-Free Survival
  • Female
  • Head and Neck Neoplasms/mortality
  • Humans
  • Immunotherapy/methods
  • Male
  • Neoplasm Recurrence, Local/mortality
  • Nivolumab
  • Prognosis
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome

Cite this

Immunotherapy for recurrent/metastatic head and neck cancer. / Alfieri, Salvatore; Cavalieri, Stefano; Licitra, Lisa.

In: Current Opinion in Otolaryngology and Head and Neck Surgery, Vol. 26, No. 2, 04.2018, p. 152-156.

Research output: Contribution to journalReview article

@article{71265c3d896f4b2b9d9ecf67a533d444,
title = "Immunotherapy for recurrent/metastatic head and neck cancer",
abstract = "PURPOSE OF REVIEW: In the last decade, after cetuximab (anti-epidermal growth factor receptor), none of the novel investigated compounds has demonstrated benefit in head and neck squamous cell cancers (HNSCC), both in advanced and curative settings. Therefore, prognosis of recurrent/metastatic (R/M) HNSCC patients remains dismal, especially in platinum-refractory cohort. In the last few years, a new important class of drugs has affirmed its role. HNSCC, even if less 'immunogenic' than other malignancies (e.g. melanoma), was field of application of several new immune agents. To date, the most important data regard drugs acting on PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) axis that is a crucial checkpoint used by tumor for immune escape. Our purpose is to summarize the results of these PD-1/PD-L1 inhibitors, outlining some critical points and few practical suggestions.RECENT FINDINGS: Nivolumab was recently approved by main regulatory agencies as second-line treatment for platinum-refractory R/M HNSCC. In the same setting, pembrolizumab was approved by FDA. Atezolizumab and durvalumab have already showed similar benefit in phase Ia and II studies, respectively.SUMMARY: Anti-PD1/PD-L1 agents are new effective therapies in R/M HNSCC. Their combination with conventional/novel compounds, as well as a better selection of responding patients, could lead to improve current results.",
keywords = "Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Carcinoma, Squamous Cell/mortality, Disease-Free Survival, Female, Head and Neck Neoplasms/mortality, Humans, Immunotherapy/methods, Male, Neoplasm Recurrence, Local/mortality, Nivolumab, Prognosis, Risk Assessment, Survival Analysis, Treatment Outcome",
author = "Salvatore Alfieri and Stefano Cavalieri and Lisa Licitra",
year = "2018",
month = "4",
doi = "10.1097/MOO.0000000000000448",
language = "English",
volume = "26",
pages = "152--156",
journal = "Current Opinion in Otolaryngology and Head and Neck Surgery",
issn = "1068-9508",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Immunotherapy for recurrent/metastatic head and neck cancer

AU - Alfieri, Salvatore

AU - Cavalieri, Stefano

AU - Licitra, Lisa

PY - 2018/4

Y1 - 2018/4

N2 - PURPOSE OF REVIEW: In the last decade, after cetuximab (anti-epidermal growth factor receptor), none of the novel investigated compounds has demonstrated benefit in head and neck squamous cell cancers (HNSCC), both in advanced and curative settings. Therefore, prognosis of recurrent/metastatic (R/M) HNSCC patients remains dismal, especially in platinum-refractory cohort. In the last few years, a new important class of drugs has affirmed its role. HNSCC, even if less 'immunogenic' than other malignancies (e.g. melanoma), was field of application of several new immune agents. To date, the most important data regard drugs acting on PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) axis that is a crucial checkpoint used by tumor for immune escape. Our purpose is to summarize the results of these PD-1/PD-L1 inhibitors, outlining some critical points and few practical suggestions.RECENT FINDINGS: Nivolumab was recently approved by main regulatory agencies as second-line treatment for platinum-refractory R/M HNSCC. In the same setting, pembrolizumab was approved by FDA. Atezolizumab and durvalumab have already showed similar benefit in phase Ia and II studies, respectively.SUMMARY: Anti-PD1/PD-L1 agents are new effective therapies in R/M HNSCC. Their combination with conventional/novel compounds, as well as a better selection of responding patients, could lead to improve current results.

AB - PURPOSE OF REVIEW: In the last decade, after cetuximab (anti-epidermal growth factor receptor), none of the novel investigated compounds has demonstrated benefit in head and neck squamous cell cancers (HNSCC), both in advanced and curative settings. Therefore, prognosis of recurrent/metastatic (R/M) HNSCC patients remains dismal, especially in platinum-refractory cohort. In the last few years, a new important class of drugs has affirmed its role. HNSCC, even if less 'immunogenic' than other malignancies (e.g. melanoma), was field of application of several new immune agents. To date, the most important data regard drugs acting on PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) axis that is a crucial checkpoint used by tumor for immune escape. Our purpose is to summarize the results of these PD-1/PD-L1 inhibitors, outlining some critical points and few practical suggestions.RECENT FINDINGS: Nivolumab was recently approved by main regulatory agencies as second-line treatment for platinum-refractory R/M HNSCC. In the same setting, pembrolizumab was approved by FDA. Atezolizumab and durvalumab have already showed similar benefit in phase Ia and II studies, respectively.SUMMARY: Anti-PD1/PD-L1 agents are new effective therapies in R/M HNSCC. Their combination with conventional/novel compounds, as well as a better selection of responding patients, could lead to improve current results.

KW - Antibodies, Monoclonal/therapeutic use

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Carcinoma, Squamous Cell/mortality

KW - Disease-Free Survival

KW - Female

KW - Head and Neck Neoplasms/mortality

KW - Humans

KW - Immunotherapy/methods

KW - Male

KW - Neoplasm Recurrence, Local/mortality

KW - Nivolumab

KW - Prognosis

KW - Risk Assessment

KW - Survival Analysis

KW - Treatment Outcome

U2 - 10.1097/MOO.0000000000000448

DO - 10.1097/MOO.0000000000000448

M3 - Review article

C2 - 29432222

VL - 26

SP - 152

EP - 156

JO - Current Opinion in Otolaryngology and Head and Neck Surgery

JF - Current Opinion in Otolaryngology and Head and Neck Surgery

SN - 1068-9508

IS - 2

ER -